Concentrix Announces Q2 2025 Earnings Release – Details Furnished in 8-K

Concentrix (Nasdaq: CNXC) filed an 8-K (Item 2.02) announcing it has released fiscal Q2 2025 results for the quarter ended May 31 2025.

Rhea-AI Filing Summary

Concentrix (Nasdaq: CNXC) filed an 8-K (Item 2.02) announcing it has released fiscal Q2 2025 results for the quarter ended May 31 2025. The company furnished, but did not file, a press release (Exhibit 99.1) containing the detailed financial statements and commentary. No numerical data, guidance, or strategic commentary is included in the 8-K text itself. The disclosure is strictly limited to the existence of the press release and therefore carries limited information for investors without referencing Exhibit 99.1. The filing reconfirms that the information is considered "furnished," not "filed," preserving safe-harbor protections.

Insights

Financial Analyst

TL;DR: Earnings released, but numbers only in Exhibit 99.1—8-K body offers no metrics.

The 8-K signals a material information event—earnings—but provides zero quantitative insight in the body text. Investors must review the attached press release to evaluate revenue, margin trends, EPS or guidance. Because the release is furnished under Item 2.02, Concentrix retains flexibility on forward-looking statements. Market impact hinges entirely on the undisclosed metrics, so at this stage the filing is informational but indeterminate for valuation models.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When did CNXC release its Q2 2025 earnings results?

Concentrix released its fiscal Q2 2025 results on June 26 2025 via a press release furnished as Exhibit 99.1.

What period do the newly reported results cover for CNXC?

The results cover the fiscal second quarter ended May 31 2025.

Where can investors find the detailed Q2 2025 financial figures for CNXC?

Detailed figures are contained in the press release (Exhibit 99.1) attached to this 8-K filing.

Is the information in CNXC's 8-K considered "filed" with the SEC?

No. Under Item 2.02, the information is "furnished", which limits its use under Section 18 of the Exchange Act.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2025 - 04:15 PM Learn about SEC filing dates

0001803599FALSE00018035992025-06-262025-06-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 26, 2025

CONCENTRIX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware			001-39494			27-1605762
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(I.R.S. Employer Identification Number)

39899 Balentine Drive, Suite 235, Newark, California						94560
(Address of principal executive offices)						(Zip Code)

(800) 747-0583

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001 per share			CNXC			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Item 2.02.    Results of Operations and Financial Condition.

On June 26, 2025, Concentrix Corporation (the “Company” or “Concentrix”) issued a press release reporting its financial results for the second quarter ended May 31, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated in this Item 2.02 by reference.

The information contained in this Current Report on Form 8-K is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference into any Concentrix filing or report with the Securities and Exchange Commission, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing or report.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press release issued by Concentrix Corporation on June 26, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 26, 2025			CONCENTRIX CORPORATION
			By:			/s/ Andre Valentine
						Andre Valentine Chief Financial Officer